PDS Biotechnology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Für PDS Biotechnology wird ein Gewinn- und Umsatzwachstum von 39.9% bzw. 62% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 44% pro Jahr steigen soll.

Wichtige Informationen

39.9%

Wachstumsrate der Gewinne

43.95%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	22.8%
Wachstumsrate der Einnahmen	62.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	06 Apr 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Amended Phase III Pathway And Long Patent Life Will Transform Future Cancer Care Potential

Apr 02Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapy treatments for HPV16 positive cancers and other solid tumors. What are the underlying business or industry changes driving this perspective?

Regulatory And Financing Risks Around HPV Cancer Program Will Eventually Reward Patience

Mar 19Catalysts About PDS Biotechnology PDS Biotechnology is a clinical stage company developing immunotherapy treatments for HPV16 positive cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?

HPV Positive Cancer Tailwinds And Trial Design Shifts Will Support Long Term Potential

Mar 05Catalysts About PDS Biotechnology PDS Biotechnology focuses on developing immunotherapies for HPV16-positive head and neck cancers and other advanced solid tumors. What are the underlying business or industry changes driving this perspective?

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Jan 13

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:PDSB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	2	-39	-46	N/A	2
12/31/2027	N/A	-39	-39	N/A	2
12/31/2026	N/A	-33	-30	N/A	2
12/31/2025	N/A	-34	-28	-28	N/A
9/30/2025	N/A	-35	-32	-32	N/A
6/30/2025	N/A	-37	-34	-34	N/A
3/31/2025	N/A	-35	-34	-34	N/A
12/31/2024	N/A	-38	-35	-35	N/A
9/30/2024	N/A	-41	-35	-35	N/A
6/30/2024	N/A	-41	-34	-34	N/A
3/31/2024	N/A	-44	-30	-30	N/A
12/31/2023	N/A	-43	-34	-34	N/A
9/30/2023	N/A	-51	-33	-33	N/A
6/30/2023	N/A	-48	-31	-31	N/A
3/31/2023	N/A	-42	-33	-33	N/A
12/31/2022	N/A	-41	-26	-26	N/A
9/30/2022	N/A	-28	-23	-23	N/A
6/30/2022	N/A	-28	-22	-22	N/A
3/31/2022	N/A	-22	-15	-15	N/A
12/31/2021	N/A	-17	-12	-12	N/A
9/30/2021	N/A	-15	-13	-13	N/A
6/30/2021	N/A	-12	-9	-9	N/A
3/31/2021	N/A	-14	-14	-14	N/A
12/31/2020	N/A	-15	-13	-13	N/A
9/30/2020	N/A	-15	-14	-14	N/A
6/30/2020	N/A	-17	-17	-17	N/A
3/31/2020	N/A	-18	-18	-18	N/A
12/31/2019	N/A	-7	-18	-18	N/A
9/30/2019	N/A	-5	N/A	-13	N/A
6/30/2019	N/A	0	N/A	-9	N/A
3/31/2019	N/A	4	N/A	-5	N/A
12/31/2018	N/A	-4	N/A	-2	N/A
9/30/2018	N/A	-2	N/A	-2	N/A
12/31/2017	N/A	-3	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PDSB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: PDSB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: PDSB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: PDSB wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: PDSB wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PDSB in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/04/09 13:07
Aktienkurs zum Tagesende	2026/04/09 00:00
Gewinne	2025/12/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

PDS Biotechnology Corporation wird von 5 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
James Molloy	Alliance Global Partners
Mayank Mamtani	B. Riley Securities, Inc.
Kalpit Patel	B. Riley Securities, Inc.

PDS Biotechnology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 8.9% to US$8.17

Price target decreased by 15% to US$10.13

Price target decreased by 7.3% to US$11.50

Price target decreased by 8.4% to US$17.67

Price target increased by 7.9% to US$19.43

Price target increased to US$18.25

Recent updates

Amended Phase III Pathway And Long Patent Life Will Transform Future Cancer Care Potential

New major risk - Financial position

Regulatory And Financing Risks Around HPV Cancer Program Will Eventually Reward Patience

HPV Positive Cancer Tailwinds And Trial Design Shifts Will Support Long Term Potential

PDS Biotechnology Corporation Receives Notice of Nasdaq Minimum Bid Price Deficiency

PDS Biotechnology Corporation Announces Adoption of Amended Protocol for Phase 3 Versatile-003 Trial Incorporating Progression

PDS Biotechnology Corporation Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

PDS Biotech Announces FDA Alignment on Use of Progression Free Survival (PFS) as Primary Endpoint

New minor risk - Share price stability

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration

New major risk - Revenue and earnings growth

Price target increased by 8.9% to US$8.17

New major risk - Shareholder dilution

PDS Biotechnology Corporation has filed a Follow-on Equity Offering in the amount of $5.277994 million.

PDS Biotechnology Corporation Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS01ADC Presented at SITC 2025

PDS Biotechnology Corporation Announces New Clinical and Translational Data on Pds0101 and Pds01adc to Be Presented At the 2025 Society for Immunotherapy of Cancer Annual Meeting

PDS Biotechnology Corporation to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expansion (CPS 1-19) Cohort in VERSATile-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

PDS Biotech Announces Final Topline Survival Data from Versatile-002 Phase 2 Trial in Head and Neck Cancer

New major risk - Financial position

PDS Biotechnology Corporation to Report Q2, 2025 Results on Aug 13, 2025

PDS Biotechnology Corporation Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

PDS Biotechnology Corporation Unveils Updated Positive Data from Versamune Hpv Abstracts

PDS Biotech Announces Positive Extended Follow-Up Data for Versamune HPV to Be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PDS Biotechnology Corporation announced that it expects to receive $20 million in funding

PDS Biotechnology Corporation, Annual General Meeting, Jun 11, 2025

Now 21% undervalued after recent price drop

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

PDS Biotechnology Corporation to Report Fiscal Year 2024 Results on Mar 27, 2025

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

PDS Biotechnology Corporation Initiates VERSATile-003 Phase 3 Clinical Trial Evaluating Versamune®? HPV in HPV16-Positive Head and Neck Cancer

Price target decreased by 15% to US$10.13

PDS Biotechnology Corporation has filed a Follow-on Equity Offering in the amount of $10.995089 million.

Pds Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic Hpv-Associated Cancers Published in Jama Oncology

Pds Biotech Announces Circulating Tumor Dna Results for Versamune®? Hpv in Immunocerv Trial Published in Clinical Cancer Research

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Price target decreased by 7.3% to US$11.50

New major risk - Revenue and earnings growth

New minor risk - Market cap size

PDS Biotechnology Corporation Provides Clinical Programs Update

PDS Biotechnology Corporation to Report Q3, 2024 Results on Nov 14, 2024

PDS Biotechnology Corporation Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

PDS Biotechnology Corporation Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

New major risk - Revenue and earnings growth

PDS Biotechnology Corporation to Report Q2, 2024 Results on Aug 13, 2024

Pds Biotech Aligns with Fda on Phase 3 Trial in Hpv16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

PDS Biotechnology Corporation(NasdaqCM:PDSB) dropped from Russell Small Cap Completeness Index

New minor risk - Market cap size

PDS Biotech Provides Data Update from Ongoing Versatile-002 Phase 2 Clinical Trial in Head and Neck Cancer

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

PDS Biotechnology Corporation to Report Q1, 2024 Results on May 15, 2024

PDS Biotechnology Corporation Appoints Stephan Toutain as Chief Operating Officer

PDS Biotechnology Corporation, Annual General Meeting, Jun 24, 2024

New minor risk - Market cap size

New minor risk - Shareholder dilution

PDS Biotechnology Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024

PDS Biotechnology Corporation Announces Publication of Preclinical Research

PDS Biotechnology Corporation Announces Executive Changes

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Pds Biotech Announces CFO Changes

Price target decreased by 8.4% to US$17.67

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients

PDS Biotechnology Corporation to Report Q3, 2023 Results on Nov 14, 2023

PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO

PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

New major risk - Financial position

PDS Biotechnology Corporation Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate Versatile-003 Trial